Today: 20 November 2025
Subscribe
Browse Tag

guidance

BigBear.ai Stock’s 300% Surge Sparks Palantir Comparisons in Defense AI Frenzy

BigBear.ai (BBAI) Soars on Q3 Beat and $250M Ask Sage Deal: Profit Returns, Guidance Reaffirmed — Nov 11, 2025

Dateline: November 11, 2025 — Shares of BigBear.ai (NYSE: BBAI) jumped sharply today after the AI defense contractor posted better‑than‑expected third‑quarter results and unveiled a definitive agreement to acquire Ask Sage, a secure generative‑AI platform, for approximately $250 million. Pre‑market gains reached roughly 19%–23% as investors reacted to the earnings beat and the strategic acquisition. TipRanks+2The Economic Times+2 Key takeaways Why BBAI is rallying today Traders are cheering a cleaner quarter that beat Street expectations alongside a deal that deepens BigBear.ai’s positioning in defense‑grade, secure generative‑AI. TipRanks highlighted the Q3 revenue beat (actual $33.1M vs. ~$31.8M consensus) and a narrower‑than‑expected
11 November 2025
 ·  ·  ·  ·  · 
JFrog (FROG) Soars 20%+ After Q3 Beat: Cloud Revenue Jumps 50%, FY2025 Guidance Raised to $523–$525M

JFrog (FROG) Soars 20%+ After Q3 Beat: Cloud Revenue Jumps 50%, FY2025 Guidance Raised to $523–$525M

JFrog Ltd. (NASDAQ: FROG) ripped higher today after posting a decisive third‑quarter beat and lifting its full‑year outlook. As of roughly 16:05 UTC, shares traded near $58.90, up ~24.6% intraday after touching an intraday high of $62.92; premarket gains topped 20% as the report hit the tape. Barron’s Key takeaways What’s driving the surge JFrog’s outperformance was broad‑based, with strength in its software supply chain platform and accelerating cloud adoption. Management highlighted new governance and AI offerings—AppTrust and AI Catalog—as catalysts helping large customers standardize on the platform. JFrog Investor Relations On the numbers, JFrog delivered total revenue of $136.9M
7 November 2025
 ·  ·  ·  ·  · 
HubSpot (HUBS) Plunges ~18% After Q3 Beat: Raised 2025 Guidance, New AI Push, and Meta’s Clara Shih Joins the Board [Nov. 6, 2025]

HubSpot (HUBS) Plunges ~18% After Q3 Beat: Raised 2025 Guidance, New AI Push, and Meta’s Clara Shih Joins the Board [Nov. 6, 2025]

HubSpot, Inc. (NYSE: HUBS) shares fell sharply on Thursday, trading down roughly 18–19% after the company reported third‑quarter results that topped estimates and lifted full‑year guidance. The selloff follows a post‑print drop in after-hours trading Wednesday and reflects investor focus on growth momentum and 2025 trajectory. As of mid‑afternoon on Nov. 6, Reuters data showed HUBS off ~19%. Reuters+1 Q3 2025 at a glance: beat on revenue and margins Context: HubSpot framed the quarter around rapid progress with AI—highlighting Customer Agent, Prospecting Agent, and more than 200 product innovations unveiled at September’s INBOUND conference alongside a new growth playbook dubbed
6 November 2025
 ·  ·  ·  ·  · 
Oscar Health (OSCR) Q3 2025: ~$3.0B Revenue, EPS Beats, 2025 Guidance Reaffirmed; Balance Sheet Simplified via Note Exchange — Nov. 6, 2025

Oscar Health (OSCR) Q3 2025: ~$3.0B Revenue, EPS Beats, 2025 Guidance Reaffirmed; Balance Sheet Simplified via Note Exchange — Nov. 6, 2025

What happened in Q3 Oscar Health reported third‑quarter revenue of $2,985,984,000 (in thousands), up from $2,423,482,000 a year ago—about 23% YoY growth, driven largely by higher membership. The medical loss ratio (MLR) increased to 88.5% (from 84.6%), which the company tied to a $130M net risk‑adjustment transfer accrual reflecting higher average market morbidity; this was partly offset by $84M of favorable prior‑period development and $22M favorable intra‑year development. The SG&A expense ratio improved to 17.5% (from 19.0%), reflecting cost discipline and fixed‑cost leverage. Business Wire On the bottom line, Oscar posted a net loss of $137.5M (–$0.53/share) versus a $54.6M
6 November 2025
 ·  ·  ·  ·  · 
AppLovin Stock Soars 520% on S&P 500 News and Earnings – Analysts Now Eyeing $810 Target

AppLovin (APP) Smashes Q3 2025 Estimates, Lifts Buyback by $3.2B, and Guides Q4 Above Street as AXON Rollout Accelerates

Dateline: Wednesday, November 5, 2025 AppLovin Corporation (NASDAQ: APP) reported blockbuster third‑quarter results after the bell today, topping Wall Street’s expectations on both the top and bottom line, boosting its share‑repurchase authorization by $3.2 billion, and setting Q4 2025 revenue guidance of $1.57–$1.60 billion, above consensus. Shares hovered around the $617 level in late trading. Key takeaways By the numbers: another step‑function higher AppLovin’s Q3 2025 revenue reached $1.405B (vs. $835M a year ago) and net income rose to $836M (vs. $434M). The company generated $1.05B in operating cash flow and reported Adjusted EBITDA of $1.158B. Management also disclosed it
5 November 2025
 ·  ·  ·  ·  · 
Figma Stock’s Post-IPO Rollercoaster: From $68 Billion Debut to Wild Drops – What’s Next for FIG?

Figma (FIG) Stock Today: Q3 2025 Earnings Beat, Raised Guidance, and What to Watch — November 5, 2025

Figma (NYSE: FIG) reported Q3 2025 results, raised full‑year guidance, and outlined AI product momentum. Here’s today’s share price, key numbers, catalysts, and risks investors are watching. At a glance Figma stock price today (NYSE: FIG) Figma shares ended today near $44.01 (-3.9%) and were modestly higher in the post‑market, as investors absorbed the earnings and fresh outlook. For context, the stock’s 52‑week high is $142.92; at today’s close FIG trades roughly ~69% below that peak. Seeking Alpha+1 Note: Intraday and post‑market figures are delayed and may differ from your broker’s real‑time quotes. What Figma reported for Q3 2025 Figma’s
5 November 2025
 ·  ·  ·  ·  · 
Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Stock Slides on Q3 Beat as Guidance Cut Shocks Investors

Biogen Inc. (Nasdaq: BIIB) is a leading neuroscience biotech known for multiple sclerosis and rare-disease therapies ts2.tech. On Oct. 30, 2025 the stock dipped after a mixed earnings release. The company beat Q3 expectations – adjusted EPS $4.81 vs. $3.88 est and $2.53 B revenue vs. $2.34 B est ng.investing.com – but lowered its full-year outlook. Biogen now expects 2025 non-GAAP EPS of $14.50–$15.00 (previously $15.50–16.00), citing an anticipated ~$1.25 per-share charge in Q4 for recent R&D deals reuters.com reuters.com. CEO Chris Viehbacher spun the quarter positively, noting “we delivered another quarter of strong financial performance driven by … momentum in our
30 October 2025
 ·  ·  ·  · 
Go toTop